In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
CTS merges with the three Red Cross testing laboratories located in Charlotte, Portland and St. Loui...